1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
H.U. Group Holdings, Inc.

H.U. Group Holdings, Inc.

MRCHF
H.U. Group Holdings, Inc.US flagOther OTC
20.90
USD
- -
- -
1.16BMarket Cap
H.U. Group Holdings, Inc.
MRCHF
(Other OTC)

Recent

price

20.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2,846.79
3,010.59
3,294.84
3,470.61
3,515.04
3,717.14
3,582.49
3,424.11
3,180.04
3,312.36
3,911.6
4,790.93
4,585.52
4,165.21
4,277.25
- -
2,119.16
Revenue per Share
191.93
211.32
254.92
261.48
274.83
-89.2
5.84
4.5
111.94
-9.06
306.38
519.55
275.51
-132.77
48.59
- -
-100.87
Basic EPS, GAAP
198.49
271.83
406.14
327.69
262.94
299.24
496.07
-26.76
-183.44
-5.9
252.57
352.88
190.67
-17.68
205.04
- -
20.29
Free Cash Flow per Basic Share
61.89
65.88
71.84
85.79
89.65
100.8
111.8
121.81
129.94
130.19
115.08
156.33
125.47
125.56
125.7
- -
62.34
Dividend per Share
1,391.31
1,536.88
1,722.68
1,896.99
1,956
1,812.88
1,706.71
1,589.44
1,572.61
1,437.88
1,621.58
1,986.77
2,138.84
1,880.52
1,805.55
- -
1,804.92
Book Value per Share
1,399.19
579.98
907.18
1,043.98
1,165.51
1,409.56
1,602.7
1,784.93
1,715.66
1,442.88
1,540.66
1,856.61
1,839.69
1,699.41
1,637
- -
1,608.45
Tangible Book Value per Share
58
58
58
59
58
57
57
57
57
57
57
57
57
57
57
- -
57
Basic Weighted Avg Shares
165,736
175,388
192,211
203,371
204,667
211,743
204,245
195,400
181,415
188,712
223,016
272,944
260,908
236,950
243,025
247,362
120,407
Sales/Revenue/Turnover
12.87
13.24
13.32
13.14
13.2
12.3
13.74
9.03
8.07
5.27
11.39
18.5
8.96
-1.71
1.09
1.93
-2.06
Operating Margin (%)
10,915
12,476
14,136
14,588
15,242
14,993
13,122
9,638
9,704
11,330
12,494
14,626
19,694
20,870
20,746
21,757
10,609
Depreciation Expense
11,174
12,311
14,871
15,322
16,002
-5,081
333
257
6,386
-516
17,468
29,599
15,676
-7,553
2,761
6,823
-5,731
Net Income, GAAP
42.04
44.21
40.38
41.36
34.23
241.25
92.5
- -
43.86
108.44
16.32
28.34
31.56
- -
15.02
21.87
- -
Effective Tax Rate (%)
6.74
7.02
7.74
7.53
7.82
-2.4
0.16
0.13
3.52
-0.27
7.83
10.84
6.01
-3.19
1.14
2.76
-4.76
Profit Margin (%)
51,340
35,860
51,093
55,020
47,196
44,124
55,584
33,895
38,407
48,600
55,095
61,787
67,480
59,150
49,705
53,071
60,359
Working Capital
2,362
28,073
23,996
21,800
26,285
9,813
7,610
5,459
32,623
55,887
68,612
65,349
69,361
68,096
62,137
45,797
60,100
LT Debt
102,797
114,521
137,333
157,346
171,849
155,700
148,086
113,224
112,971
103,228
115,299
140,176
150,045
142,505
137,292
137,470
136,079
Total Equity
11.46
9.55
9.25
8.7
8.91
-18.76
1.22
- -
5.74
-0.49
11.37
17.35
7.14
- -
1
1.7
- -
Return on Invested Capital (%)
13.78
11.54
11.73
11.67
11.5
-4.29
0.31
- -
5.45
-0.37
10.89
16.64
8.27
- -
1.74
4.09
- -
Return on Capital (%)
14.47
14.44
15.65
14.48
14.22
-4.68
0.33
0.27
7.08
-0.6
20.04
28.79
13.35
-6.61
2.63
6.68
-5.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,849
- -
20,000
LT Borrowings
60,100
- -
60,100
LT Finance Leases
7,996
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
- -
57
Market Capitalization
164,502
146,070
130,428

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
123,220
- -
127,387
Cash, Cash Equivalents & STI
40,135
- -
47,018
Accounts Receivable, Net
47,425
- -
45,497
Inventories
22,461
- -
22,200
Total Current Liabilities
64,070
- -
67,028
Payables & Accruals
- -
- -
- -
ST Debt
13,849
- -
20,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.55%
4.01%
0.13%
Free Cash Flow
-526.7%
-266.08%
43.37%
Net Income, GAAP
-145.31%
-23.04%
147.12%
Sales/Revenue/Turnover
2.03%
2.63%
1.78%
Total Cash Common Dividend
3.11%
3.18%
-0.07%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
56,620
59,923
60,968
59,439
236,950
2025
- -
- -
- -
- -
243,025
2026
- -
- -
- -
- -
247,362

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-19.66
- -
- -
- -
-132.77
2025
- -
- -
- -
- -
48.59
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62.9
- -
- -
- -
125.56
2025
- -
- -
- -
- -
125.7
2026
- -
- -
- -
- -
- -
Similar Companies
Sapporo Clinical Laboratory Inc. (9776.T)
IQVIA Holdings Inc. (IQV)
Chembio Diagnostics, Inc. (CEMI)
Vijaya Diagnostic Centre Limited (VIJAYA.BO)
Intelligent Bio Solutions Inc. (INBS)
Labcorp Holdings Inc. (0JSY.L)
Business
H.U. Group Holdings, Inc. is a Japan-based company specializing in healthcare services, in vitro diagnostics (IVD), lab testing, and related healthcare support services. The company operates primarily through its four core business segments: Lab Testing and Its Related Services, In-Vitro Diagnostics, Healthcare-related Services, and Research & Development. Within Lab Testing, H.U. Group provides comprehensive clinical laboratory testing including infectious disease, cancer, and lifestyle disease diagnostics with advanced technologies such as chemiluminescence and immunoassays. Its Diagnostics segment manufactures and markets in-vitro diagnostic reagents and instruments. Healthcare-related Services include sterilization services, operating room support, endoscopy room assistance, medical equipment maintenance, logistics management, and nursing care equipment rental and sales. The company targets medical institutions and healthcare providers primarily in Japan and increasingly in international markets through its subsidiaries. Founded in 2014 and headquartered in Tokyo, H.U. Group is focused on creating a healthy society by providing novel, value-added healthcare products and services. Recent strategic developments include the company’s ongoing integration strategy begun in 2022, positioning it as a second founding phase with bold structural reforms for sustainable growth and synergy creation across its operations. In 2019, it acquired Fluxus, Inc. (U.S.) and ADx NeuroSciences N.V. (Belgium), expanding its CDMO (contract development and manufacturing organization) capabilities. Recently, it expanded its neuro testing portfolio with new fully automated assays, reinforcing its research and development efforts. H.U. Group also completed a significant equity buyback in 2025 to enhance shareholder value. Operational reforms include unifying domestic sales structures and strengthening group integration in R&D and sales to enhance profitability in its Lab Testing segment. The company continues to invest in the H.U. Bioness Complex for full-scale operations supporting diagnostics and therapeutics innovation. H.U. Group remains committed to expanding its product portfolio and geographic reach while maintaining regulatory compliance and clinical validation standards essential to its healthcare and diagnostic services.